Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study
- Registration Number
- NCT00937846
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
GSK1034702 is being developed for improving cognitive impairment in diseases such as Alzheimer's disease and schizophrenia. This study will be done in healthy men to investigate how much of the study drug gets into the brain. This will be done using Positron Emission Tomography (PET).
- Detailed Description
This is an open label, single dose, non-randomized PET study in healthy male subjects to ascertain if GSK1034702 is crossing the blood-brain barrier to enable it to elicit a central effect. GSK1034702 has been shown in vitro to be a substrate for human Pgp, therefore the distribution of GSK1034702 into human brain could be adversely affected. This use of PET in conjunction with radioactively labelled GSK1034702 will help ascertain the role Pgp plays in limiting brain penetration in the presence and absence of a pharmacological relevant oral non labelled dose of 5 mg. Subjects will have an MRI scan to aid definition of brain anatomy, a baseline PET scan and a post-dose PET scan. For each subject the study will consist of at least three visits; screening visit, scanning day and follow-up.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 4
- Generally healthy.
- Male between 35 and 55 years of age.
- Willing to use appropriate contraception method.
- Weight more than 50 kg.
- BMI within the range 19 - 29 kg/m2.
- Adequate blood supply to the hand.
- Abuse of drugs or alcohol.
- Smoker or history of regular use of tobacco- or nicotine-containing products in the past 6 months.
- ECG abnormality (personal or family history).
- Psychiatric disorder.
- Asthma or a history of asthma.
- Medical illness.
- Worked as a welder, metal worker or machinist.
- Suffers from claustrophobia or would be unable to lie still in a PET or MRI scanner for 1-2 hours.
- Has a cardiac pacemaker or other electrical device or ferromagnetic metal foreign bodies.
- Neurological disorder
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description GSK1034702 GSK1034702 Single oral 5 mg dose in liquid formulation
- Primary Outcome Measures
Name Time Method Volume of distribution of [11C]GSK1034702 at tracer and pharmacological doses. Scanning day
- Secondary Outcome Measures
Name Time Method The kinetic rate constants at tracer and pharmacological doses. Scanning day GSK1034702 PK parameters: Cmax; tmax; AUC(0-t). Scanning day Safety and tolerability endpoints consisting of: AEs; 12-lead ECG; 12 lead digital Holter and lead II telemetry; vital signs; clinical laboratory evaluations. 2 weeks
Trial Locations
- Locations (1)
GSK Investigational Site
🇬🇧London, United Kingdom